INCY 250117 72.50C (INCY250117C72500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

INCY250117C72500

Watchlist

2.65
+0.06+2.32%

15min DelayTrading Jan 8 12:41 ET

3.20High2.65Low

Intraday

5D
Daily

News

Wednesday Market Falls, Quantum Computing Pulls Back Hard on Treasury Yield Crunch | Live Stock
Kevin Travers11:06 ET
Truist Financial Maintains Incyte(INCY.US) With Hold Rating, Maintains Target Price $74
Moomoo NewsJan 8 07:34 ET · Ratings
Truist Financial Maintains Incyte(INCY.US) With Hold Rating, Announces Target Price $74
Moomoo NewsJan 8 02:33 ET · Ratings
Incyte (INCY) Receives a Hold From Truist Financial
TipRanksJan 8 02:15 ET · Ratings
Tuesday Market Pulls Back After Nvidia All Time High | Wall Street Today
Kevin TraversJan 7 16:22 ET
Market Sells CES Tech News, ISM Tuesday as Nvidia Champions Robots Monday | Live Stock
Kevin TraversJan 7 10:46 ET

Comments

韭菜变主力

Nov 19, 2024 12:59

$Merck & Co (MRK.US)$ $Incyte (INCY.US)$ is a great company. Buying it would be a good decision, unless Merck massively overpays.

Tynkr Lab

Oct 29, 2024 19:14

Tech Stocks Surge While Dow Falters as U.S. Markets Prepare for Key Data

Click Here: TYNKR LAB™
U.S. stock markets closed with mixed results, reflecting cautious investor sentiment as major tech earnings approached alongside key economic data. $Dow Jones Industrial Average (.DJI.US)$ fell by 0.36%, while $S&P 500 Index (.SPX.US)$ and $Nasdaq Composite Index (.IXIC.US)$ posted gains of 0.16% and 0.81%, respectively. This divergence highlights sector-specific movements and investor positioning ahead ...

🚨 This Week’s PDUFAs:
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...

Trytosaveabit

Aug 14, 2024 16:41

News

$Syndax Pharmaceuticals (SNDX.US)$ $Incyte (INCY.US)$ Reuters
5 mins ago
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (Axatilimab-Csfr) for the Treatment of Chronic Graft-Versus-Host Disease (Gvhd)